Overview

Reducing the Overall Risk Level in Patients Suffering From Metabolic Syndrome

Status:
Completed
Trial end date:
2007-03-01
Target enrollment:
Participant gender:
Summary
This study will evaluate the efficacy of a multi factorial preventive scheme of action (including fluvastatin and valsartan) to reduce the overall risk level in patients with metabolic syndrome.
Phase:
Phase 4
Details
Lead Sponsor:
Novartis
Treatments:
Fluvastatin
Hydrochlorothiazide
Valsartan